Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p95HER2.CAR-TECH2Me in Advanced HER2-Positive Cancers
NCT07593820Phase 1Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Apr 2026
- Primary completion
- Jun 2030
- Modality
- CAR-T Cells, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of p95HER2.CAR-TECH2Me in gastric cancer (GC), breast cancer and endometrial cancer (EC), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Adverse Events at 3 months, Clinically Significant Abnormalities in Clinical Safety Laboratory Tests at 3 months and 5 more. Started Apr 2026; status: recruiting.
02
Drugs
p95HER2.CAR-TECH2Me
03
Conditions
gastric cancer (GC)breast cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT07593820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593820.